Evidence map›Paper›PMID 39379773›Full record

ArticleEndocrine2025

Therapeutic efficacies of remnant ablation and radioiodine adjuvant therapy in differentiated thyroid cancer.

Yanlin Liu, Shuhui Huang, Xiaohui Li, Tian Tian, Rui Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanlin Liu *Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China.
Shuhui Huang *Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China.
Xiaohui LiDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China.
Tian TianDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China.
Rui HuangDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China. huang_rui@scu.edu.cn.ORCID 0000-0003-3191-0528

Funding

The Science & Technology Department of Sichuan Province 24ZDYF0154
6 · The paper itself

Abstract

backgroundSuccessful ablation in

methodsThis retrospective study included patients with DTC who underwent initial

resultsA total of 232 patients were included, 91.8% (213/232) of patients achieved SRA, only 8.1% (19/232) failed RA (FRA). Among the 213 patients in the SRA group, 70.4% (150/213) achieved SRAT and 29.6% (63/213) failed RAT (FRAT). Only pre-ablation sTg >10 ng/mL (OR = 46.968, 95% CI 9.731-226.699, P < 0.001) was an independent risk factor predicting the failure of RAT. The prognostic analysis included 215 patients, and 6.1% (13/215) were classified as persistent/recurrent disease at the last follow-up. Both pre-ablation sTg >10 ng/mL (HR = 4.765, 95% CI 1.371-16.566, P = 0.014) and FRAT (HR = 10.104, 95% CI 1.071-95.304, P = 0.043) independently predicted persistent/recurrent disease.

conclusionsRA is easy to achieve successfully, whereas RAT evaluation provides greater value than RA for prognosis prediction. For patients with low Tg levels and no imaging evidence of disease, routine Dx-WBS during follow-up has minimal significance.

Indexed as

Iodine RadioisotopesThyroid NeoplasmsAdolescentAdultAgedFemaleHumansMaleMiddle AgedPrognosisRadiotherapy, AdjuvantRetrospective StudiesThyroglobulinThyroidectomyTreatment OutcomeYoung AdultIodine-131Iodine RadioisotopesThyroglobulinDifferentiated thyroid cancerRadioiodine adjuvant therapyRemnant ablationTherapeutic efficacy

Identifiers

PMID39379773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.